Market Opportunity for Veeva Systems


Published on

How big of an opportunity does Veeva have?

Published in: Economy & Finance, Business
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Market Opportunity for Veeva Systems

  1. 1. The Big Drivers Moving Veeva Forward
  2. 2. A Quick Primer • Veeva was founded by Peter Gassner, a former Salesforce (NYSE: CRM) executive, who saw a cloud need in pharma. • Veeva’s platform is still hosted on • Through three different platforms—CRM, Vault, and Network—Veeva helps manage data.
  3. 3. The Industry is Outdated  E-mail is used by 69% of study sponsors for communication with contract research organizations (CROs).  Paper shipments are used by 57% of these partners for communication.  These are both difficult to organize and unsecured when compared to cloud solutions.
  4. 4. Businesses Think Using Veeva- Type Systems is Advantageous  56% of eTMF (Veeva-like) users do so for cost savings.  55% do so to speed up the start of studies.  49% do so to improve the monitoring of studies.  45% believe that using eTMF systems increase readiness for regulatory inspection.
  5. 5. Those Who Have Already Adopted eTMF Are Happy The results were a little surprising, in that the most advantageous benefits of using eTMF systems didn’t meet up with the perceived benefits perfectly.  68% of eTMF respondents said the systems helped track and view documents in real-time.  65% said that it was easier to search for and find relevant documents.  Tracking execution and design metrics for clinical trials vastly improved document quality, audit readiness, collaboration, and compliance.
  6. 6. But, Hardly Anyone is Using eTMFs  13% of trial sponsors only use paper-based tracking.  26% use internal file sharing systems.  18% use publicly available cloud-sharing systems.  30% use content management systems.  Only 13% use dedicated eTMF applications like Veeva Vault.
  7. 7. What this Means for Investors…  Some may be skeptical of the findings, as the study was carried out by Veeva and paints a picture of a huge market opportunity.  That being said, there’s little doubt that the companies providing the most value for streamlining clinical trials will win the most contracts over the coming years.  Veeva’s stock will likely continue to be volatile, and is still priced for heavy growth, trading at 86 times expected 2014 earnings.
  8. 8. More Than One Way to Make Money in Healthcare While Veeva represents a potentially lucrative business in healthcare, there are other options, like this one highlighted in the Motley Fool’s special free report: A Blockbuster to Make Every Healthcare Company Jealous